| Literature DB >> 25667600 |
Abstract
Understanding the transition of bacterial species from commensal to pathogen, or vice versa, is a key application of evolutionary theory to preventative medicine. This requires working knowledge of the molecular interaction between hosts and bacteria, ecological interactions among microbes, spatial variation in bacterial prevalence or host life history, and evolution in response to these factors. However, there are very few systems for which such broad datasets are available. One exception is the gram-negative bacterium, Helicobacter pylori, which infects upwards of 50% of the global human population. This bacterium is associated with a wide breadth of human gastrointestinal disease, including numerous cancers, inflammatory disorders, and pathogenic infections, but is also known to confer fitness benefits to its host both indirectly, through interactions with other pathogens, and directly. Outstanding questions are therefore why, when, and how this bacterium transitions along the parasitism-mutualism continuum. We examine known virulence factors, genetic predispositions of the host, and environmental contributors that impact progression of clinical disease and help define geographical trends in disease incidence. We also highlight the complexity of the interaction and discuss future therapeutic strategies for disease management and public health in light of the longstanding evolutionary history between the bacterium and its human host.Entities:
Keywords: antibiotic resistance; carcinogenic bacteria; gut microbiota; host–parasite coevolution; human health; microbiome; probiotics; virulence factors
Year: 2014 PMID: 25667600 PMCID: PMC4310578 DOI: 10.1111/eva.12231
Source DB: PubMed Journal: Evol Appl ISSN: 1752-4571 Impact factor: 5.183
Examples of current evidence in support of both harmful and beneficial effects correlated with Helicobacter pylori infection.
| Effect of infection | Affect on health | Citation |
|---|---|---|
| Increased prevalence of gastric cancer | (−) | Uemura et al. ( |
| Increased risk of infection | (−) | Shahinian et al. ( |
| with | (−) | Clemens et al. ( |
| Increased prevalence of peptic ulcers | (−) | Maeda et al. ( |
| Chronic and acute gastritis | (−) | Graham et al. ( |
| Suppression of bacteria causing tuberculosis | (+) | Perry et al. ( |
| Reduced risk of eczema | (+) | Amberbir et al. ( |
| Reduced risk of gastroesophogeal reflux disease | (+) | Sonnenberg et al. ( |
| Protection against diarrheal diseases | (+) | Cohen et al. ( |
| Reduced risk of esophageal cancer | (+) | Islami and Kamangar ( |
| Reduction of asthma and allergy | (+) | Chen and Blaser ( |
| Reduced risk of irritable bowel disease | (+) | Luther et al. ( |
But see Qian et al. (2011).
Figure 1Schematic summarizing the key genetic, ecological, and evolutionary factors known to influence the transition of Helicobacter pylori along the parasitism–mutualism continuum. Factors known to increase potential pathogenicity are in red, those that are involved in colonization and survival in the human host, but which have no direct evidence of conferring either cost or benefit to the host are in black, and factors that are thought to be associated with conferred benefits to the host (either directly or indirectly) are in green. Further factors that are predicted from theory but which have not been examined empirically are included in italics. Details of each association are discussed within the main text. References: (1) Oleastro and Ménard (2013); (2) Censini et al. (1996); (3) Maeda et al. (1998); (4) Persson et al. (2011); (5) Kodaman et al. (2014); (6) Gaddy et al. (2013); (7) Atherton et al. (1996); (8) León-Barúa et al. (2006); (9) Anderson and May (1982); (10) Eaton et al. (1992); (11) Ottemann and Lowenthal (2002); (12) Tsuda et al. (1994); (13) Gobert et al. (2001); (14) Bonis et al. (2010); (15) Salama et al. (2013); (16) Chen and Blaser (2007); (17) Arnold et al. (2011).